Fosamax Osteonecrosis of the Jaw Prognosis: Long-term Outcome of Osteonecrosis of the Jaw after Fosamax Exposure

Latest update (2026-05)

FDA enforcement record (Ongoing): This recall is being conducted due to out of specification assay results in a limited number of bottles that were stored on side. [source]

General Health Context and Medication Safety

The legacy context of general health and science information has historically provided broad, foundational knowledge about medication safety and human physiology. Within this framework, public health communications have long emphasized the importance of understanding drug side effects and long-term outcomes, particularly for widely prescribed treatments. This general health perspective serves as a necessary starting point for recognizing that all pharmaceutical interventions carry potential risks that require careful monitoring and patient education. (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56)

Transition to Occupational and Clinical Exposure Concerns

Transitioning from this broad health awareness to a more specific occupational concern, the focus narrows to the implications of bisphosphonate exposure, particularly in clinical and industrial settings. While general health information addresses population-level risks, occupational health considerations demand heightened scrutiny of repeated or prolonged exposure scenarios. The bridge between these domains lies in recognizing that certain medications, when encountered in professional environments—such as during manufacturing, handling, or administration—may present distinct risk profiles that differ from standard patient use. This pivot from general health literacy to occupational exposure awareness underscores the need for specialized protocols in workplaces where such compounds are regularly present, moving beyond passive information consumption to active risk management in professional practice.

Fosamax and Osteonecrosis of the Jaw: Evidence and Risk Factors

Fosamax (alendronate) is a bisphosphonate medication approved for the treatment and prevention of osteoporosis in postmenopausal women, treatment to increase bone mass in men with osteoporosis, treatment of glucocorticoid-induced osteoporosis, and treatment of Paget's disease of bone (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The optimal duration of use has not been determined, and for patients at low risk for fracture, drug discontinuation after 3 to 5 years of use may be considered (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Osteonecrosis of the jaw (ONJ) is a recognized adverse effect associated with bisphosphonate use, including Fosamax. The condition can occur spontaneously but is generally associated with tooth extraction and/or local infection with delayed healing (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Known risk factors for ONJ include invasive dental procedures (e.g., tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (e.g., chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders such as periodontal and/or other pre-existing dental disease, anemia, coagulopathy, infection, and ill-fitting dentures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The risk of ONJ may increase with duration of exposure to bisphosphonates (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The time to onset of symptoms after starting Fosamax can vary from one day to several months (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). In placebo-controlled clinical studies of Fosamax, the percentages of patients with these symptoms were similar in the Fosamax and placebo groups (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Most patients had relief of symptoms after stopping the drug, but a subset had recurrence of symptoms when rechallenged with the same drug or another bisphosphonate (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). For patients requiring invasive dental procedures, discontinuation of bisphosphonate treatment may reduce the risk for ONJ (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).

Long-term Prognosis and Risk Reduction

Regarding long-term prognosis, a cohort study among cancer-free female patients aged 40-89 with or at risk for osteoporosis in the United Kingdom Clinical Practice Research Datalink found that ONJ risk was threefold higher after 2-3 years of treatment and eightfold higher after 10 years compared with past use (https://pubmed.ncbi.nlm.nih.gov/39400702/). Absolute risks remained low, approximately 0.05% after 5 years, and diminished after discontinuation (https://pubmed.ncbi.nlm.nih.gov/39400702/). This suggests that while the relative risk increases with longer exposure, the absolute risk of developing ONJ remains small for osteoporosis patients. The study also indicates that risk diminishes after stopping treatment, which aligns with clinical guidance that discontinuation may reduce risk. Multiscale characterization of jawbone tissue provides comprehensive information that can help better understand jawbone-specific responses to bone-related complications, including bisphosphonate-related osteonecrosis of the jaw (https://pubmed.ncbi.nlm.nih.gov/40345077/). This research may inform future prognostic assessments by elucidating the underlying mechanisms of ONJ development.

Adequacy of Warnings and Clinical Guidance

In terms of adequacy of warnings, the prescribing information for Fosamax includes a specific section on osteonecrosis of the jaw (Section 5.4) that describes the condition, associated risk factors, and clinical considerations (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56; https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The label notes that ONJ has been reported in patients taking bisphosphonates, including Fosamax, and outlines known risk factors such as invasive dental procedures, cancer diagnosis, concomitant therapies, poor oral hygiene, and co-morbid disorders (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The label also advises that discontinuation of bisphosphonate treatment may reduce the risk for ONJ in patients requiring invasive dental procedures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). These warnings provide clinicians and patients with information to assess and manage the risk. For affected patients, prognosis-related considerations include the potential for symptom relief after discontinuation, though a subset may experience recurrence if rechallenged with a bisphosphonate (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The timeline between exposure and documented harm can range from one day to several months after starting the drug, and risk increases with longer duration of use (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56; https://pubmed.ncbi.nlm.nih.gov/39400702/). Overall, while ONJ is a serious condition, the absolute risk in osteoporosis patients is low, and prognosis improves after drug cessation.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Community Resource & Benefit Desk

Request archival records or inquire about member-exclusive transition and benefit programs.

Frequently Asked Questions

What is the long-term prognosis for Osteonecrosis of the Jaw after Fosamax exposure?

The long-term prognosis for ONJ after Fosamax exposure is generally favorable for most patients. Most patients experience relief of symptoms after stopping the drug, although a subset may have recurrence if rechallenged with a bisphosphonate. Absolute risk of ONJ in osteoporosis patients is low (approximately 0.05% after 5 years) and diminishes after discontinuation. (https://pubmed.ncbi.nlm.nih.gov/39400702/)

How does the duration of Fosamax use affect the risk of developing ONJ?

The risk of ONJ increases with longer duration of bisphosphonate use. A cohort study found that risk was threefold higher after 2-3 years and eightfold higher after 10 years compared to past use. However, absolute risks remain low and diminish after stopping treatment. (https://pubmed.ncbi.nlm.nih.gov/39400702/)

What are the known risk factors for developing ONJ while taking Fosamax?

Known risk factors include invasive dental procedures (tooth extraction, dental implants, boney surgery), cancer diagnosis, concomitant therapies (chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders such as periodontal disease, anemia, coagulopathy, infection, and ill-fitting dentures. (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1)

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Fosamax exposure and a confirmed Osteonecrosis of the Jaw diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.